The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-ResistantStaphylococcus aureusBacteriolysis
Abstract
Bacteriophage-derived lysins are cell-wall-hydrolytic enzymes that represent a potential new class of antibacterial therapeutics in development to address burgeoning antimicrobial resistance. CF-301, the lead compound in this class, is in clinical development as an adjunctive treatment to potentially improve clinical cure rates ofStaphylococcus aureusbacteremia and infective endocarditis (IE) when used in addition to antibiotics.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 01, 2019
- Source ID
- 10.1128/aac.02291-18
Entities
People
- Arnold S. Bayer
- Assaf Raz
- Cara Cassino
- Chiara Indiani
- Karen Sauve
- Raymond Schuch
- Wessam Abdelhady
- Yan Q. Xiong
Organizations
- Congressionally Directed Medical Research Programs
- Harbor–UCLA Medical Center
- The Rockefeller University
- University of California, Los Angeles